TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2220725

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (1 g/10 ml) plus cimetidine (300 mg qid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cimetidine (300 mg qid)
Number of subjects: 36
Study: 370976

Group type: EXPERIMENTAL
Intervention: Na‐ioxitalamate
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Na‐methylglucamine‐diatrizoate
Number of subjects: 1628
Study: 31633789

Group type: EXPERIMENTAL
Intervention: Lower-dose venlafaxine (≤150 mg/d)
Number of subjects: 227
Study: 31034045

Group type: EXPERIMENTAL
Intervention: Prefeed gastric residual evaluation (residual group)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Omission of gastric residual evaluation (no residual group)
Number of subjects: 143
Study: 30079643

Group type: EXPERIMENTAL
Intervention: SC patients
Number of subjects: 98

Group type: COMPARATOR
Intervention: SS patients
Number of subjects: 98
Study: 25707477

Group type: EXPERIMENTAL
Intervention: NNC0109‐0012 (3 mg/kg per week, subcutaneously)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 23388003

Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 10 mg once daily for 35±4 days
Number of subjects: 8101

Group type: COMPARATOR
Intervention: Enoxaparin, 40 mg once daily for 10±4 days followed by placebo
Number of subjects: 8101
Study: 21163281

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg kg(‐1) ingested 60 min before and 45 min after exercise in 33°C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA) in 33°C
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) in 12°C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA) in 12°C
Number of subjects: 11
Study: 19474135

Group type: EXPERIMENTAL
Intervention: 60 g low-TFA lipids/d (0.54 g/d; n = 21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ruminant TFA-rich lipids (4.86 g/d; n = 21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Industrial TFA-rich lipids (5.58 g/d; n = 21)
Number of subjects: 63
Study: 17190428

Group type: EXPERIMENTAL
Intervention: Glucocorticoid group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contrast group
Number of subjects: 30
Study: 15209643

Group type: EXPERIMENTAL
Intervention: Galantamine at a maintenance dose of 16 or 24 mg/d
Number of subjects: 659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study: 11575284

Group type: EXPERIMENTAL
Intervention: 6 mg of ADL 8‐2698
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 1 mg of ADL 8‐2698
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 9783800

Group type: EXPERIMENTAL
Intervention: Thiotepa (TTP) 5 mg/kg x 2 days (days -4, -3) along with busulfan (BU) 4 mg/kg x 4 days and cyclophosphamide (CY) 60 mg/kg x 2 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard BU-CY conditioning regimen (historical control)
Number of subjects: 33
Study: 7868872

Group type: EXPERIMENTAL
Intervention: High salt intake (200 mmol/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low salt intake (50 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium depletion in salt-resistant hypertensives
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sodium replete state in salt-resistant patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation of plasma calcitonin gene-related peptide with plasma renin activity in salt-resistant patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Changes in plasma calcitonin gene-related peptide due to salt intake
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone levels
Number of subjects: 15
Study: 2908008

Group type: EXPERIMENTAL
Intervention: Urapidil 15 mg intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urapidil (both doses)
Number of subjects: 8
Study: 31704549

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 28566525

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (40.2 mg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MIX (22.8 mg all-rac-alpha-tocopherol acetate + 20.1 mg RRR-alpha-tocopherol)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ARAC (45.5 mg all-rac-alpha-tocopherol acetate)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 89

Group type: COMPARATOR
Intervention: MIX and ARAC
Number of subjects: 89
Study: 24750558

Group type: EXPERIMENTAL
Intervention: Tapentadol PR 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tapentadol PR 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tapentadol PR 300 mg/day plus pregabalin 300 mg/day
Number of subjects: 0
Study: 24006819

Group type: EXPERIMENTAL
Intervention: Diets containing 3, 5, and 7% cinnamon powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what diet)
Number of subjects: 0
Study: 21633600

Group type: EXPERIMENTAL
Intervention: Absorbable sutures (Vicryl)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-absorbable sutures (Silk)
Number of subjects: 125
Study: 19178610

Group type: EXPERIMENTAL
Intervention: Group I (Intact pleural cavity)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Group II (Opened pleural cavity)
Number of subjects: 320
Study: 16544235

Group type: EXPERIMENTAL
Intervention: Outpatient education program (AFAS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham-training (control group)
Number of subjects: 120
Study: 15286116

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11677701

Group type: EXPERIMENTAL
Intervention: Intervention clinics (trained health visitors)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 25
Study: 9562314

Group type: EXPERIMENTAL
Intervention: Collar therapy for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collar therapy for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collar therapy
Number of subjects: 20
Study: 8179463

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT) including breathing retraining, muscle relaxation, cognitive reframing, and exposure to interoceptive and agoraphobic stimuli for 12 sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonprescriptive treatment (reflective listening) for 12 sessions.
Number of subjects: 0
Study: 2888638

Group type: EXPERIMENTAL
Intervention: Ranitidine 250 mg hs for four days prior to chloroquine administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chloroquine sulfate (300‐mg base) only
Number of subjects: 10
Study: 29630101

Group type: EXPERIMENTAL
Intervention: CT-guided implantation of 125I seeds in combination with chemotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Simple chemotherapy
Number of subjects: 76
Study: 27158849

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT‐AD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 89
Study: 24047799

Group type: EXPERIMENTAL
Intervention: Rotarix™ vaccine
Number of subjects: 102074
Study: 23538618

Group type: EXPERIMENTAL
Intervention: Traditional corneal cross-linking (CXL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transepithelial corneal cross-linking (CXL)
Number of subjects: 35
Study: 19861187

Group type: EXPERIMENTAL
Intervention: Aerosolized Triviraten vaccine (including Rubini mumps strain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injected MMR II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injected Moraten measles vaccine (twice the dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerosolized mumps vaccine (Leningrad-Zagreb strain)
Number of subjects: 0
Study: 18720121

Group type: EXPERIMENTAL
Intervention: Eccentric training with the AirHeel Brace
Number of subjects: 116

Group type: COMPARATOR
Intervention: Eccentric training without the AirHeel Brace
Number of subjects: 116
Study: 12081199

Group type: EXPERIMENTAL
Intervention: Short-term preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 1306
Study: 9833911

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg per day initially, tapered to 10 mg daily after 8 weeks) and azathioprine (50 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7978715

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg twice daily
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clarithromycin 2000 mg twice daily
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clarithromycin (all dosages)
Number of subjects: 154
Study: 2688237

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine/prilocaine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Infiltration analgesia with 1% carbocaine (mepivacaine)
Number of subjects: 13
Study: 999302

Group type: EXPERIMENTAL
Intervention: Fluorouracil and 0.5% triamcinolone acetonide cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorouracil alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diluted (0.1%) triamcinolone acetonide cream
Number of subjects: 0
Study: 31692152

Group type: EXPERIMENTAL
Intervention: Genetically predicted 10% higher CRP concentration
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Plasma CRP ≥2.0 mg/l
Number of subjects: 991
Study: 30649381

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (ASMQ)
Number of subjects: 0
Study: 26869229

Group type: EXPERIMENTAL
Intervention: 10-minute clown visit
Number of subjects: 200

Group type: COMPARATOR
Intervention: 10-minute humorous video clip
Number of subjects: 200
Study: 26059332

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg twice daily in combination with dacarbazine 1000 mg/m² on Day 1 of every 21-day cycle
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dacarbazine 1000 mg/m²
Number of subjects: 128
Study: 23493728

Group type: EXPERIMENTAL
Intervention: Cryptococcal-specific CD4(+) T-cell responses characterized by IFN-γ and TNF-α production
Number of subjects: 44
Study: 21705396

Group type: EXPERIMENTAL
Intervention: Real acupuncture + relaxation response (AR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham acupuncture + relaxation response (SR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Real acupuncture + health education (AE)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham acupuncture + health education (SE)
Number of subjects: 130
Study: 19098188

Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous catheter drainage in patients with sterile necrosis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous catheter drainage in patients with infected necrosis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous catheter drainage in patients with multisystem organ failure
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous catheter drainage in patients without multisystem organ failure
Number of subjects: 35
Study: 16699660

Group type: EXPERIMENTAL
Intervention: SITA Standard (SS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Full Threshold (FT)
Number of subjects: 31
Study: 15302454

Group type: EXPERIMENTAL
Intervention: Opalescence 10% (O10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Opalescence 15% (O15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Opalescence 20% (O20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whiteness 10% (W10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whiteness 16% (W16)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (C-untreated)
Number of subjects: 60
Study: 11770869

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9832976

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg) and benserazide (25 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no incentive)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no levodopa)
Number of subjects: 44
Study: 8508870

Group type: EXPERIMENTAL
Intervention: Single dose intravenous antibiotic prophylaxis (4 g piperacillin and 800 mg tinidazole 30 minutes before surgery)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Multiple dose intravenous antibiotic prophylaxis (4 g piperacillin 30 minutes before surgery, 4 g piperacillin 8 hours after, and 4 g piperacillin and 800 mg tinidazole 16 hours after the first dose)
Number of subjects: 66
Study: 31034033

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Non-LNS groups (iron and folic acid + calcium, multiple micronutrients)
Number of subjects: 961
Study: 29436896

Group type: EXPERIMENTAL
Intervention: Combined music and Tai Chi for three months
Number of subjects: 107

Group type: COMPARATOR
Intervention: Routine health education delivered monthly by community nurses (Control)
Number of subjects: 107
Study: 26865496

Group type: EXPERIMENTAL
Intervention: Center-based physical activity (PA) intervention for a median of 2.7 years
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Health education (control group) for a median of 2.7 years
Number of subjects: 1633
Study: 23345601

Group type: EXPERIMENTAL
Intervention: 300 mg/day avocado-soybean unsaponifiable (ASU-E)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 23060025

Group type: COMPARATOR
Intervention: Combined trabeculotomy‐trabeculectomy with mitomycin C (CTTM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined trabeculotomy‐trabeculectomy with mitomycin C and deep sclerectomy (CTTM-DS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTTM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CTTM-DS
Number of subjects: 20
Study: 21568147

Group type: EXPERIMENTAL
Intervention: Standard triple therapy (Group A): omeprazole, amoxicillin, metronidazole, and bismuth, twice daily for 2 weeks
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin based triple therapy (Group C): omeprazole and amoxicillin, twice daily for 2 weeks, and ciprofloxacin twice a day for the first week
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (Group D): omeprazole, amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for the remaining 5 days, all twice daily for 10 days
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group (Group B): omeprazole, amoxicillin, and clarithromycin, twice daily for 10 days
Number of subjects: 428
Study: 18082484

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (transfer for routine PCI within 6 hours of fibrinolysis)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard treatment after fibrinolysis
Number of subjects: 1200
Study: 16513681

Group type: EXPERIMENTAL
Intervention: A23G SNP in XPA (GG genotype)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: XPA genotype
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: XPA haplotypes
Number of subjects: 886
Study: 14966633

Group type: EXPERIMENTAL
Intervention: Doxycycline slow-release gel
Number of subjects: 30
Study: 11113239

Group type: EXPERIMENTAL
Intervention: 20 g Cr/day for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9229987

Group type: EXPERIMENTAL
Intervention: Remifentanil with isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil with propofol
Number of subjects: 40
Study: 8232134

Group type: EXPERIMENTAL
Intervention: Flurbiprofen mouth wash 10 ml, 3 times daily for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouth wash 10 ml, 3 times daily for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 3457810

Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine (CH)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.05% metronidazole (MD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.01% quinine sulphate inactive control (PL)
Number of subjects: 23
Study: 30857410

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy (target systolic blood pressure <120 mm Hg)
Number of subjects: 14094

Group type: COMPARATOR
Intervention: Standard blood pressure treatment (target <140 mm Hg)
Number of subjects: 14094

Group type: COMPARATOR
Intervention: Logistic regression approach
Number of subjects: 14094

Group type: EXPERIMENTAL
Intervention: X-learner approach
Number of subjects: 14094
Study: 29435996

Group type: EXPERIMENTAL
Intervention: Type II minimally‐invasive extracorporeal circuit (MiECC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional extracorporeal circuits (CECC)
Number of subjects: 50
Study: 26821688

Group type: EXPERIMENTAL
Intervention: Quadripolar LV lead
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bipolar LV lead
Number of subjects: 43
Study: 25415695

Group type: EXPERIMENTAL
Intervention: 100 kV with 90 mL iopromide 370 mg I/mL at 3.5 mL/s
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 100 kV with 44% reduction in contrast volume
Number of subjects: 83
Study: 23017784

Group type: EXPERIMENTAL
Intervention: Cola (1 liter daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Deionized water (1 liter daily)
Number of subjects: 13
Study: 20415698

Group type: EXPERIMENTAL
Intervention: Bosentan (250 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 10
Study: 18001455

Group type: EXPERIMENTAL
Intervention: Total salpingectomy during abdominal hysterectomy (Group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Partial removal of fallopian tubes during abdominal hysterectomy (Group 2)
Number of subjects: 24
Study: 15664574

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Experienced chest radiologists
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Consensus with CAD
Number of subjects: 20
Study: 12391944

Group type: EXPERIMENTAL
Intervention: Hospital at-home care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hospital day-care unit
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 42
Study: 9931532

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 mg/m2/d)
Number of subjects: 54
Study: 7772643

Group type: EXPERIMENTAL
Intervention: Metyrapone 750 mg followed by oCRF 0.3 microgram/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: oCRF following metyrapone pretreatment
Number of subjects: 20
Study: 1969869

Group type: EXPERIMENTAL
Intervention: Procaterol 25 micrograms escalating to 100 micrograms, and 100 micrograms twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lower dose of procaterol
Number of subjects: 45
Study: 375050

Group type: EXPERIMENTAL
Intervention: Alice/R‐75 2-dose vaccine
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Alice/R‐75 1-dose vaccine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo 2-dose
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Alice strain monovalent influenza A vaccine
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: R‐75 strain monovalent vaccine
Number of subjects: 319
Study: 31753903

Group type: EXPERIMENTAL
Intervention: Face-to-face training with certified instructor, using Laerdal Little Anne manikins for 20 minutes.
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Virtual reality training using the Lifesaver VR app for 20 minutes, practicing on a pillow while wearing VR goggles and headphones.
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Both training methods (face-to-face and VR) evaluated for overall CPR performance using a European Resuscitation Council endorsed checklist.
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires post-training.
Number of subjects: 50000
Study: 28189659

Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing (HDD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Common hemostatic sponge (CollaPlug, Zimmer Dental)
Number of subjects: 20
Study: 26183257

Group type: EXPERIMENTAL
Intervention: Cluster Sets (CLU) [4 × (2 × 5) with 1.5 min rest between sets and 30 s rest between clusters]
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional Sets (TRD) [4 × 10 repetitions with 2 min rest]
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cluster Sets (CLU)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional Sets (TRD)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both conditions (CLU and TRD)
Number of subjects: 23
Study: 23191994

Group type: EXPERIMENTAL
Intervention: High-fibre LGI diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lower-fibre HGI diet
Number of subjects: 16
Study: 20569998

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 70
Study: 19387173

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (target glucose 100-150 mg/dl)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard intermittent insulin bolus (treat glucose > 150 mg/dl)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard intermittent insulin bolus
Number of subjects: 236
Study: 17290437

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cobalt-chromium stent (CCS)
Number of subjects: 104
Study: 14522441

Group type: EXPERIMENTAL
Intervention: N'Dribala (Cochlospermum planchonii)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 85
Study: 11128858

Group type: EXPERIMENTAL
Intervention: GAKIC (glycine and L-arginine salt of alpha-ketoisocaproic acid calcium)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isocaloric sucrose (control)
Number of subjects: 13